| 1047 |
Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1060 |
Newer Anti-TB Drugs: Bedaquiline [Bdq] |
02/06/2024 |
DR-TB and PMDT |
| 1104 |
Use of M/XDR-TB Regimen in People Living with HIV [PLHIV] |
02/06/2024 |
DR-TB and PMDT |
| 1064 |
Weight Band-wise Dosages of DR-TB Drugs for Adults |
02/06/2024 |
DR-TB and PMDT |
| 1065 |
Drug-resistant TB Service Linkages to Private Sectors |
02/06/2024 |
DR-TB and PMDT |
| 1066 |
Mandatory Establishment of DR-TB Centres in All Medical Colleges |
02/06/2024 |
DR-TB and PMDT |
| 1067 |
Functions of District DR-TB Centre |
02/06/2024 |
DR-TB and PMDT |
| 1068 |
Requirements for Establishing District DR-TB Centres |
02/06/2024 |
DR-TB and PMDT |
| 1077 |
Baseline Second-line Drug-susceptibility Testing |
02/06/2024 |
DR-TB and PMDT |
| 1093 |
Prevention of Drug-resistance |
02/06/2024 |
DR-TB and PMDT |
| 1098 |
DR-TB Services Referral Linkage Scenario: Patient Notified from the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1099 |
DR-TB Service Referral Linkages Scenario: DR-TB Patient Referred for Treatment from the Private Sector with Bacteriological Confirmation in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1100 |
DR-TB Service Referral Linkages Scenario: DR-TB Patient Referred for Treatment from the Private Sector with Treatment Initiated in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1101 |
Rapid Molecular Drug-resistance Testing |
02/06/2024 |
DR-TB and PMDT |
| 1103 |
Clinical Monitoring of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1105 |
Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1106 |
Use of Longer Oral M/XDR-TB Regimen in Severe Forms of Extrapulmonary TB and TB Meningitis |
02/06/2024 |
DR-TB and PMDT |
| 1107 |
Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1108 |
Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation |
02/06/2024 |
DR-TB and PMDT |
| 1109 |
Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1110 |
Replacement Sequence in the H Mono/Poly DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1112 |
Use of Isoniazid [H] Mono/Poly DR-TB Regimen in Special Situations |
02/06/2024 |
DR-TB and PMDT |
| 1113 |
Adverse Drug Events: H Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1114 |
Interim Treatment Outcomes of DR-TB Cases |
02/06/2024 |
DR-TB and PMDT |
| 1115 |
Flow Chart of H Mono/Poly DR-TB Patients from Diagnosis to Treatment Outcome |
02/06/2024 |
DR-TB and PMDT |
| 1116 |
Flow Chart of MDR/RR-TB Patients on Shorter Oral Bedaquiline-containing Regimen from Diagnosis to Treatment Outcome |
02/06/2024 |
DR-TB and PMDT |
| 1117 |
Need for Palliative Care in DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1118 |
Preventive Treatment for Contacts of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1230 |
State Programmatic Management of Drug-resistant TB [PMDT] Committee |
02/06/2024 |
DR-TB and PMDT |
| 1233 |
Cascade of Care for DR-TB Patients in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
